J Rhinol > Volume 29(2); 2022
Hong and Park: The Roles of Vascular Endothelial Growth Factor, Angiostatin, and Endostatin in Nasal Polyp Development

Abstract

Background and Objectives

Microvascular remodeling and angiogenesis are elements of tissue remodeling characteristic of chronic inflammatory diseases, including nasal polyps (NPs). Angiogenesis reflects the balance between the actions of pro- and anti-angiogenic factors. Many pro-angiogenic factors are known, including vascular endothelial growth factor (VEGF). A number of anti-angiogenic factors (e.g., angiostatin and endostatin) also has been identified. Our objective was to assess the roles of VEGF, angiostatin, and endostatin in NP development.

Methods

The expression levels of VEGF, angiostatin, and endostatin were measured in NPs harvested during endoscopic endonasal surgery and compared with those in inferior turbinate mucosa (control) samples acquired from patients with hypertrophic rhinitis without allergy. Western blotting and immunohistochemical staining were used to analyze all samples.

Results

The levels of VEGF and angiostatin were significantly higher in the NP subjects than in the controls. Neither the VEGF/angiostatin ratio nor the endostatin level differed significantly between the two groups. However, the VEGF/endostatin ratio was significantly higher in the NP than in the control group. Both the NP and control tissues were diffusely immunoreactive for VEGF, angiostatin, and endostatin.

Conclusion

NP-associated hypoxia can elevate angiostatin level; moreover, an imbalance in the VEGF/endostatin ratio can contribute to NP formation.

INTRODUCTION

Angiogenesis is a complex process in which blood vessels sprout from the existing microvasculature. Angiogenesis involves the coordination of many events, including disruption of the basement membrane (BM) by proteases, endothelial cell (EC) proliferation and migration, lumen formation, reassembly of the BM, recruitment of pericytes and/or vascular smooth muscle cells, vascular maturation, and, finally, new blood flow [1].
Under physiological conditions, angiogenesis is controlled by the balance among endogenous stimulators and inhibitors. Under pathological conditions (including tumor growth and chronic inflammation), the imbalance between stimulator and inhibitor levels triggers the so-called “angiogenic switch” [2]. Various pro-angiogenic factors are known, including vascular endothelial growth factor (VEGF) [3]. An increasing number of anti-angiogenic factors (including angiostatin and endostatin) have also been described [4]. VEGF is one of the most powerful angiogenic factors, directly affecting EC proliferation, migration, and tube formation under physiological and pathological conditions [5]. VEGF also plays an important role during the regulation of capillary actions and BM permeability of nasal polyps (NPs), leading to extensive edema and polyp growth [6].
Angiostatin exerts its anti-angiogenic effects by inducing EC apoptosis [79] and impairing EC proliferation [10], migration, and tube formation [11]. Endostatin induces EC apoptosis via various signaling pathways [12,13], and it suppresses EC migration, adhesion, and proliferation [14,15].
The role of angiostatin or endostatin in NP pathophysiology (angiogenesis) remains unclear. For this reason, we compared the accurate figure of angiostatin, endostatin, and VEGF in NPs and inferior turbinate mucosal tissues (control) to reveal it.

METHODS

Subjects

Thirteen patients with NPs and twelve patients having nasal septum deviation were enrolled at the department of Otorhinolaryngology-head & neck surgery, Inje University Busan Paik Hospital, Busan, Korea. NPs were diagnosed using the previously known criteria for chronic rhinosinusitis with NPs [16]. Written informed consent was obtained from all patients. Inje University Busan Paik Hospital Ethics Committee approved this study (IRB No. 16-0213). A NP was defined as visible polyp growing from the middle nasal meatus into the nasal cavity by endoscopy, affecting the ethmoid and maxillary sinuses as computed tomography of the paranasal sinus revealed. NPs were removed from the region of the middle meatus at the commencement of operation. Control inferior turbinate and nasal mucosal tissues were harvested from patients without evidence of NPs, to avoid any possibility to share chronic mucosal inflammation, who went through septoplasty with inferior turbinoplasty. No subject had any history of asthma, aspirin sensitivity, or nasal allergy. Allergies were diagnosed based on both a relevant history and the results of the Multiple Allergen Stimulation Test (MAST Immunosystems, Mountain View, CA, USA) and blood eosinophil count. No patient had taken systemic or topical steroids, antihistamines, macrolide antibiotics, or nonsteroidal anti-inflammatory drugs for 4 weeks before the procedure.

Reagents

3,3′-Diaminobenzidine (DAB) was purchased from Abcam Inc. (Cambridge, MA, USA). Antibodies against VEGF (cat. no. 250907) and endostatin (cat. no. 251198) were obtained from Abbiotec Inc. (San Diego, CA, USA). Antibodies against angiostatin (cat. no. bs-1828R) were purchased from Bioss Inc. (Woburn, MA, USA). Horseradish peroxidase (HRP)-conjugated anti-goat (SC-2020) antibodies were used as secondary antibodies (Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Protein extraction and Western blot analysis

Tissues were mortar-ground into fine powders in liquid nitrogen, transferred to 1.5-mL microfuge tubes, and lysis buffer (G-biosciences, St. Louis, MO, USA) was added. The proteins were separated on polyacrylamide mini-gels and transferred to nitrocellulose membranes (GE Healthcare Life Sciences, Little Chalfont, UK). Following overnight incubation with the appropriated primary antibody, the membranes were incubated with a secondary antibody conjugated to HRP. The immunoreactive bands were visualized using an electrochemiluminescence detection system (Pierce Biotechnology, Inc., Rockford, IL, USA).

Immunohistochemistry

Formalin-fixed paraffin-embedded NP and inferior turbinate mucosal samples were sectioned at a 5-μm thickness, mounted on poly-L-lysine coated slides, and deparaffinized and rehydrated via a series of xylene and alcohol. After rinsing with 1X phosphate-buffered saline, the sections were immersed in Target Retrieval Solution (pH 6.0; Dako, Carpinteria, CA, USA) for 5 min at 121°C in a pressure cooker and allowed to cool for 20 min. Endogenous peroxidase activity was blocked by incubation with Peroxidase-Blocking Solution (Dako) for 10 min at room temperature, and the slides were then washed in phosphate-buffered saline and immersed in Antibody Diluent with background-reducing components (Dako) for 1 h. Sections were incubated overnight with anti-VEGF, -angiostatin, and -endostatin antibodies at 4°C and then incubated for 1 h at room temperature with donkey anti-goat IgG HRP-bound secondary antibodies. DAB served as a chromogen, and Mayer’s hematoxylin was used for counterstaining.

Statistical analysis

The results were analyzed using GraphPad Prism ver. 5 (GraphPad Software Inc., La Jolla, CA, USA). Mann–Whitney U test was performed for data, which were presented as means±standard deviations. Statiscal significance was defined as a p-value <0.05.

RESULTS

Levels of vascular endothelial growth factor, angiostatin, and endostatin protein

The relative VEGF protein level normalized to that of GAPDH was 3.07±2.79 in the NPs and 0.45±0.28 in the inferior turbinate mucosal samples. The figures for angiostatin were 3.81±2.34 and 0.93±0.83, while those for endostatin were 1.17±0.22 and 1.19±0.21, respectively (Fig. 1). Both the VEGF and angiostatin levels were higher in the NPs than in the control samples with statistical significance (p=0.001 for VEGF, p=0.001 for angiostatin), but the endostatin levels did not differ significantly (p>0.05) (Table 1).

The vascular endothelial growth factor/angiostatin and vascular endothelial growth factor/endostatin ratios

The VEGF/angiostatin ratio was 0.84±0.53 in the NPs and 2.21±5.34 in the control samples. However, the difference between two ratios was not significant (p>0.05). The VEGF/endostatin ratio was 2.81±2.57 in the NPs and 0.41±0.30 in the control samples, thus significantly higher in the NPs (p= 0.002) (Table 1).

Immunohistochemical staining

VEGF immunoreactivity was evident principally in stromal cells, including ECs, fibroblasts, and inflammatory cells, in both the control and NP samples (Fig. 2). Angiostatin immunoreactivity was evident principally in the submucosal inflammatory cells of the stroma and ECs in both the control and NP samples (Fig. 3). Finally, endostatin immunoreactivity was strong in the ECs of stromal vessels in both samples (Fig. 4).

DISCUSSION

NPs are a chronic inflammatory disease in the mucosa of nose featuring infiltration by inflammatory cells (especially eosinophils) and tissue remodeling, including fibrosis, thickening of BM, and accumulation of extracellular matrix. Microvascular remodeling and angiogenesis are components of such remodeling in many chronic inflammatory diseases [17].
Of the many angiogenetic cytokines, VEGF is particularly important, being a major enhancer for vascular permeability in some inflammatory lesions [18,19]. VEGF could encourage microvascular permeability, contributing to the edema frequently evident in NPs. An increase in microvascular permeability triggers extravasation of plasma proteins participating in accumulation of the extracellular matrix, thereby accelerating NP growth [15]. We found that the VEGF level was higher in NPs than control samples.
Angiostatin induces EC apoptosis directly without any proliferative increase for compensation, resulting in a net reduction in EC numbers, in turn altering signaling by focal adhesion kinase and disrupting the normal turnover of such adhesions [20,21]. In addition, angiostatin decreases proliferation and migration of EC, and tube formation by inhibiting activation of VEGF- and the fibroblast growth factor-dependent extracellular signal-regulated protein kinases [22]. Angiostatin may exert its anti-angiogenic effects through binding to adenosine triphosphate (ATP) synthase in cell surface, thus depriving ECs of ATP [8]. However, in a mouse model of chronic hypoxia, angiostatin overexpression in lung tissue aggravated the development of pulmonary and right ventricular hypertension [23]. Also, hypoxia may play a role in NP initiation [24]. We found that the angiostatin level was higher in NPs than in control samples with statistical significance. We assume that chronic hypoxia in nasal cavity probably increase the angiostatin level, which may induce NP formation.
Endostatin, produced by various types of cells, is a strong endogenous inhibitor of angiogenesis [25]. Endostatin elevates apoptosis of EC by decreasing the expression levels of Bcl-xL and Bcl-2 (anti-apoptotic proteins) [12] and causing activation of caspase-3 [26]. Endostatin in extracelluar space inhibits the phosphorylation of signal-regulated protein kinases in fibroblast growth factor- and VEGF-induced EC cultures of artery, without hampering by the receptor binding of growth factors [12]. Also, endostatin reduces the production of a proinflammatory cytokine, tumor necrosis factor alpha [27]. Endostatin inhibits neoangiogenesis under various pathologies normally characterized by increased angiogenesis, including cancer [25], arthritis [27], and ulcerative colitis [28].
VEGF and endostatin frequently function as an inducer and inhibitor, respectively, of angiogenesis. The VEGF/endostatin ratio reflects the status of the angiogenic switch [29]. In sputum, the VEGF levels were higher in asthmatics than control subjects with significance. Moreover, the VEGF/endostatin ratio in asthmatics was higher than that in controls with significance [30]. Also, the endostatin level was significantly lower in seasonal allergic rhinitis patients exhibiting bronchial hyper-reactivity than in those lacking bronchial hyper-reactivity. We found that the VEGF level was higher in NPs than in controls with significance and the endostatin level did not differ between two groups. Also, the VEGF/endostatin ratio in NPs was significantly higher than in controls. We assume that a VEGF/endostatin imbalance in NPs means that hyper-reactivity in nasal mucosa can contribute to NP development.

Conclusion

The VEGF and angiostatin levels were higher in NPs than control samples. We suggest that nasal hypoxia elevates the angiostatin level, contributing to NP formation. Also, the elevated VEGF/endostatin ratio in NPs mean angiogenic switch due to hyper-reactivity, which may contribute to NP formation.

Limitations

In this paper only the expression of protein was confirmed, but it was difficult to confirm the expression of gene level. Further research is required.

Notes

Availability of Data and Material

All data generated or analyzed during the study are included in this published article.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Seong Kook Park. Data curation: Seong Kook Park. Investigation: Tae Ui Hong. Methodology: Tae Ui Hong, Seong Kook Park. Project administration: Tae Ui Hong, Seong Kook Park. Writing—original draft: Tae Ui Hong. Writing—review & editing: Seong Kook Park.

Funding Statement

This work was supported by the 2017 Inje University Busan Paik Hospital research grant.

Fig. 1
Western blotting exploring differences in the expression levels of VEGF, angiostatin, and endostatin between IT mucosal samples (n=12) and NPs (n=13). Equal amounts of cell lysates were separated on sodium dodecyl sulfate-polyacrylamide gels and transferred to membranes, which were then probed with antibodies against VEGF, endostatin, and angiostatin. Proteins were visualized using an electrochemiluminescence detection system. VEGF, vascular endothelial growth factor; IT, inferior turbinate; NP, nasal polyp.
jr-2021-00400f1.jpg
Fig. 2
VEGF immunoreactivities of NPs and the IT mucosae. The horseradish peroxidase-based 3,3′-diaminobenzidine method was used. VEGF immunoreactivity was evident principally in stromal cells, including endothelial cells, fibroblasts, and inflammatory cells in both IT samples (A and B) and NP tissues (C and D) (magnification, ×5 [A and C] and ×20 [B and D]). VEGF, vascular endothelial growth factor; NP, nasal polyp; IT, inferior turbinate.
jr-2021-00400f2.jpg
Fig. 3
Angiostatin immunoreactivities of NPs and IT mucosal samples. The horseradish peroxidase-based 3,3′-diaminobenzidine method was used. Immunoreactivity was evident principally in the submucosal inflammatory cells of the stroma and endothelial cells of both the IT samples (A and B) and NPs (C and D) (magnification, ×2.5 [A and C] and ×10 [B and D]). NP, nasal polyp; IT, inferior turbinate.
jr-2021-00400f3.jpg
Fig. 4
Endostatin immunoreactivities in NPs and IT mucosal samples. The horseradish peroxidase-based 3,3′-diaminobenzidine method was used. Endostatin was strongly expressed in endothelial cells of the stromal vessels of both the IT tissues (A and B) and NPs (C and D) (magnification, ×5 [A and C] and ×10 [B and D]). NP, nasal polyp; IT, inferior turbinate.
jr-2021-00400f4.jpg
Table 1
Demographic data of the levels of VEGF, angiostatin, endostatin and ratio of VEGF/angiostatin and VEGF/endostatin in IT mucosal samples and NPs
Specimen number VEGF Angiostatin Endostatin VEGF/angiostatin VEGF/endostatin





IT NP IT NP IT NP IT NP IT NP
1 0.06 4.80 0.19 5.05 1.28 0.94 0.32 0.95 0.05 5.09
2 0.09 5.59 0.19 4.89 1.64 0.96 0.48 1.14 0.05 5.81
3 0.24 6.16 0.76 6.23 1.32 1.09 0.32 0.99 0.18 5.63
4 0.50 9.79 1.13 6.72 1.23 1.17 0.44 1.46 0.41 8.35
5 0.17 2.15 0.66 1.96 1.47 1.09 0.26 1.10 0.12 1.97
6 0.52 2.75 1.94 1.38 1.12 1.31 0.27 1.99 0.46 2.09
7 1.00 2.17 1.00 5.97 1.00 1.11 1.00 0.36 1.00 1.96
8 0.83 0.85 0.63 4.06 1.01 1.10 1.31 0.21 0.82 0.77
9 0.61 0.46 0.23 1.95 1.04 0.93 2.65 0.24 0.59 0.50
10 0.41 0.38 0.02 0.40 1.06 1.74 19.00 0.94 0.39 0.22
11 0.49 1.59 1.68 2.08 0.97 1.13 0.29 0.77 0.51 1.41
12 0.43 2.72 2.77 7.27 1.21 1.20 0.16 0.37 0.36 2.26
13 0.56 1.63 1.38 0.34 0.41
Average 0.45 3.07 0.93 3.81 1.19 1.17 2.21 0.84 0.41 2.81
STD 0.28 2.79 0.83 2.34 0.21 0.22 5.34 0.53 0.30 2.57
U value 18 17 69 66 20
p-value 0.001 0.001 0.646 0.529 0.002

VEGF, vascular endothelial growth factor; IT, inferior turbinate; NP, nasal polyp; STD, standard deviation; U value, Mann–Whitney U test value

REFERENCES

1) Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1(1):27–31.
crossref pmid pdf
2) Ribatti D. Endogenous inhibitors of angiogenesis: a historical review. Leuk Res 2009;33(5):638–44.
pmid
3) Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9(3):211–20.
crossref pmid
4) Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev 2000;19(1–2):181–90.
pmid
5) Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039–49.
crossref pmid pmc
6) Coste A, Brugel L, Maître B, Boussat S, Papon JF, Wingerstmann L, et al. Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor. Eur Respir J 2000;15(2):367–72.
crossref pmid
7) Chen YH, Wu HL, Li C, Huang YH, Chiang CW, Wu MP, et al. Anti-angiogenesis mediated by angiostatin K1-3, K1-4 and K1-4.5. Involvement of p53, FasL, AKT and mRNA deregulation. Thromb Haemost 2006;95(4):668–77.
crossref pmid
8) Moser TL, Stack MS, Asplin I, Enghild JJ, Højrup P, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999;96(6):2811–6.
crossref pmid pmc
9) Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A 2001;98(12):6656–61.
pmid pmc
10) Sharma MR, Tuszynski GP, Sharma MC. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem 2004;91(2):398–409.
crossref pmid
11) Troyanovsky B, Levchenko T, Månsson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001;152(6):1247–54.
pmid pmc
12) Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274(17):11721–6.
crossref pmid
13) Kang HY, Shim D, Kang SS, Chang SI, Kim HY. Protein kinase B inhibits endostatin-induced apoptosis in HUVECs. J Biochem Mol Biol 2006;39(1):97–104.
crossref pmid
14) Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277(31):27872–9.
crossref pmid
15) Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 2001;98(3):1024–9.
crossref pmid pmc
16) Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, et al. Rhinosinusitis: developing guidance for clinical trials. Otolaryngol Head Neck Surg 2006;135(5 Suppl):S31–80.
crossref pmid pdf
17) McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001;164(10 Pt 2):S39–45.
crossref pmid
18) Hamada N, Kuwano K, Yamada M, Hagimoto N, Hiasa K, Egashira K, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005;175(2):1224–31.
crossref pmid
19) Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669–76.
crossref pmid pdf
20) Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 1998;95(10):5579–83.
crossref pmid pmc
21) Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998;92(12):4730–41.
pmid
22) Redlitz A, Daum G, Sage EH. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J Vasc Res 1999;36(1):28–34.
crossref pmid pdf
23) Pascaud MA, Griscelli F, Raoul W, Marcos E, Opolon P, Raffestin B, et al. Lung overexpression of angiostatin aggravates pulmonary hypertension in chronically hypoxic mice. Am J Respir Cell Mol Biol 2003;29(4):449–57.
crossref pmid
24) Chien CY, Tai CF, Ho KY, Kuo WR, Chai CY, Hsu YC, et al. Expression of hypoxia-inducible factor 1alpha in the nasal polyps by real-time RT-PCR and immunohistochemistry. Otolaryngol Head Neck Surg 2008;139(2):206–10.
crossref pmid pdf
25) O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88(2):277–85.
crossref pmid
26) Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997;91(4):443–6.
crossref pmid
27) Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005;84:Suppl 2. 1144–55.
crossref pmid
28) Tolstanova G, Deng X, Khomenko T, Garg P, Paunovic B, Chen L, et al. Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis. Life Sci 2011;88(1–2):74–81.
crossref pmid
29) Hu Y, Hu MM, Shi GL, Han Y, Li BL. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer. Eur J Surg Oncol 2014;40(9):1136–42.
crossref pmid
30) Asai K, Kanazawa H, Otani K, Shiraishi S, Hirata K, Yoshikawa J. Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects. J Allergy Clin Immunol 2002;110(4):571–5.
crossref pmid


Editorial Office
101 Hyundai ESA Apt., 20, Hyoryeong-ro 77-gil, Seocho-gu, Seoul 06628, Republic of Korea
Tel: +82-2-3461-9945    Fax: +82-2-3461-9947    E-mail: office@j-rhinology.org                

Copyright © 2022 by Korean Rhinologic Society.

Developed in M2PI

Close layer
prev next